Zenday App vs MacroFactor: an adaptive algorithm meets a very unusual input

Why does a GLP-1 need its own app at all?

Because the medication changes what the problem is. Appetite drops sharply, often unevenly across the dose cycle, and the old skill — eating less than you want — stops being the thing you need help with. Three new problems take its place: getting enough protein into a much smaller appetite, protecting muscle during rapid loss, and getting through the side-effect weeks that follow every dose increase.

Side effects are the single most common reason people stop treatment. That's the failure mode a GLP-1 companion exists to prevent, and it's the reason a general-purpose tracker struggles here no matter how good it is at its own job.

Zenday App was founded in 2025 by Emily Carter, who was taking a GLP-1 herself, and built with a doctor-led team. It now reports more than a million users. Its three pillars are dose-linked daily guidance, side-effect management, and privacy — it runs in a browser, so there's no app icon on your phone and no app-store purchase trail.

Why does a GLP-1 complicate an adaptive model?

MacroFactor's core insight is that your energy expenditure can be inferred from the relationship between what you eat and how your weight moves, and updated weekly. It works well, and it's the best implementation of that idea available.

A GLP-1 introduces two things the model didn't have in mind. First, intake swings sharply with the dose cycle — the days after an injection often look nothing like the days before the next one. Second, titration steps change appetite abruptly, so the pattern the algorithm learned last month may not describe this month.

This isn't a flaw in MacroFactor; it's a mismatch. Adaptive systems work best on inputs that vary smoothly. Zenday App treats the dose cycle as a known structure rather than noise to be smoothed away, which is the better fit for the situation.

Credit where it's due on rigour

MacroFactor is one of very few apps in our database with zero dark patterns logged. It doesn't manufacture urgency, doesn't guilt you for a missed day, and explains its own reasoning in more detail than most clinical tools. On our Daily UX and Evidence axes it scores well above category median, and it deserves to.

Its absence of a free tier is the one commercial choice we'd push back on. At roughly $71.99 a year with no trial-free path, it asks for commitment before you know whether the model suits you.

What MacroFactor is genuinely best at

No app in this comparison is bad, and pretending otherwise would make this page less useful. Here's where MacroFactor leads:

• The adaptive expenditure algorithm — genuinely the most sophisticated modelling in consumer nutrition
• Evidence-led design, with an unusually transparent explanation of its own methods
• Excellent macro coaching for people with consistent habits
• No dark patterns and no engagement-bait — a rare and welcome position

The cost framing that actually matters

GLP-1 medication commonly runs $500–$1,000 a month. Against that, the difference between two companion apps is a rounding error — usually less than two days of prescription. The question worth asking isn't which app is cheaper. It's which one makes the expensive thing work harder, and which one keeps you on treatment through the weeks when most people stop.